Navigation Links
Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
Date:4/18/2011

and has been instrumental in its growth during his six and a half years at the Company," said Mr. Crowley. "He has a strong track record of success throughout his 18-year career in the field of rare disease drug development, having overseen the advancement of novel therapies through development into commercialization. I am confident Matt has the experience and capabilities to lead Amicus during this important time in the Company's history."

Mr. Patterson joined Amicus in December 2004 as Chief Business Officer and became Chief Operating Officer in September 2006. He was recently appointed President in February 2011 in recognition of his significant contributions to the Company's success. Prior to Amicus, Mr. Patterson served in positions of increasing responsibility at biopharmaceutical companies focused on rare disease drug research, development, and commercialization, including BioMarin Pharmaceutical Inc. and Genzyme Corporation.

Mr. Crowley will serve as Executive Chairman and a member of the Board of Directors until October 2011, with a possible extension for up to three months upon the mutual agreement of Mr. Crowley and the Company.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company at the forefront of developing therapies for rare diseases.  The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program is in Phase 3 for the treatment of Fabry disease. 

FOLD-G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
2. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
3. Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
4. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
5. Amicus Therapeutics Announces Third Quarter 2010 Financial Results
6. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
7. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
8. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
9. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
10. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
11. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Lpath, Inc. (NASDAQ: LPTN ... reported interim results in a Phase 2a single-arm, ... a treatment for metastatic renal cell carcinoma (RCC) ... therapy involving a VEGF inhibitor (e.g., Sutent®/ sunitinib ... (e.g., Afinitor®/everolimus), with a maximum of three failed ...
(Date:7/24/2014)... 2014  Market Diagnostics International LLC ("MDxI") today ... , a data resource that sets a new ... and identifying target In Vitro Diagnostics (IVD) customers. ... provides IVD manufacturers with accurate and comprehensive information ... and consistent definitions of laboratory categories and institutional ...
(Date:7/24/2014)... , July 24, 2014   Cypher ... today a co-promotion agreement with Illumina to facilitate ... sequence data for precision medicine and clinical trials. ... companies, through Illumina,s sales force, a solution including ... for data analytics and storage, and Cypher Genomics, ...
Breaking Medicine Technology:Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 3Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 4MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 2Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 3
... IRVINE, Calif., June 12 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, announced today that three ... of Masimo PVI as a noninvasive and continuous measure ... week at the European Society of Anaesthesiology (ESA) Annual ...
... Safety and Biologic Activity Data Reviewed in End of Phase ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a ... treatment of cardiovascular and metabolic disease, announced today that an ... VIA-2291 (atreleuton), was recently held with the U.S. Food and ...
Cached Medicine Technology:New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
(Date:7/24/2014)... Mass. (PRWEB) July 24, 2014 Dr. ... Beth Israel Deaconess Medical Center in Boston, is the ... . Dr. Oettgen brings his considerable experience in the ... EBSCO Health . , Dr. Oettgen received his ... Medicine and completed his residency at Tufts New England ...
(Date:7/24/2014)... July 24, 2014 The first-ever successful ... a patient’s blood has been achieved by NFCR-supported scientist ... General Hospital. This is an important milestone on the ... selecting the best treatment for each patient. , ... “They often acquire new genetic features that make them ...
(Date:7/24/2014)... LSE Health and the European Heart Academy (EHA) ... pleased to announce the launch of a new, ... field of cardiovascular sciences. , The MSc in ... aims to equip cardiovascular specialists with the health ... take on advisory, management or leadership roles within ...
(Date:7/24/2014)... Texas at Arlington professor who co-authored a book ... in community revitalization has been awarded the Community ... Martinez-Cosio, associate professor in the School of Urban ... week at the society,s national conference, along with ... academic coordinator in the Urban Studies and Planning ...
(Date:7/24/2014)... seldom sufficient to read the declaration of contents if you ... fact, to do this you need to be a highly ... you can look directly into the molecular structure of the ... Engineering, is almost both, as he has developed a method ... biological samples. , The ,Fingerprints, of a Substance ...
Breaking Medicine News(10 mins):Health News:DynaMed™ Names Peter Oettgen, MD as Deputy Editor of Cardiology 2Health News:DynaMed™ Names Peter Oettgen, MD as Deputy Editor of Cardiology 3Health News:New Blood Test Advances Individualized Cancer Therapy and Cuts Down on Need for Painful Biopsies 2Health News:LSE and ESC announce the launch of a new executive-style MSc 2Health News:Strategy for community development partnerships earns award for UT Arlington professor 2Health News:Chemist develops X-ray vision for quality assurance 2Health News:Chemist develops X-ray vision for quality assurance 3
... of Emerging Models of Care , , ... The Case Management Society of America ( CMSA ) will host ... the Grand Hyatt San Antonio in San Antonio, Texas . ... Association of Social Workers, DMAA: The Care Continuum Alliance, and The ...
... retail opportunities for fresh roasted fortified coffee. , ... ... first in caffeine and fat burning fresh roasted coffee products, has ... partnership in the coffee industry will push the JavaFit brand ...
... Individuals reporting a history of periodontal disease were ... a risk factor for heart disease, compared to ... according to an American Journal of Cardiology ... from Columbia University Medical Center and NewYork-Presbyterian Hospital, ...
... L. Chao today announced the appointment of five members to ... (NACOSH). The committee, established under the Occupational Safety and ... health and human services on occupational safety and health programs. ... the advisory committee members, willingness to contribute their time and ...
... The Lose For Good(TM) Campaign Reaches $1 Million Dollar Donation ... Banks in Need , , ... WTW ) is pleased to announce the donation of one ... Strength and Action Against Hunger. The donation was made ...
... Inc. (Nasdaq: ALXN ) today announced that Dr. ... at the 20th Annual Piper Jaffray Health Care Conference in ... 2, 2008. , , An ... You can access the webcast at: www.alexionpharm.com . An ...
Cached Medicine News:Health News:2009 Collaborative Practice Summit to Bring Together Health Care Leaders 2Health News:2009 Collaborative Practice Summit to Bring Together Health Care Leaders 3Health News:JavaFit, Distributors of Vitamin Infused Fresh Roasted Coffee, Announces Partnership With CLR Roasters 2Health News:Presence of gum disease may help dentists and physicians identify risk for cardiovascular disease 2Health News:Presence of gum disease may help dentists and physicians identify risk for cardiovascular disease 3Health News:U.S. Labor Secretary Elaine L. Chao announces new membership of OSHA advisory committee 2Health News:U.S. Labor Secretary Elaine L. Chao announces new membership of OSHA advisory committee 3Health News:Weight Watchers Members and Online Subscribers Lose an Estimated 4 Million Pounds in Six Week Period 2Health News:Weight Watchers Members and Online Subscribers Lose an Estimated 4 Million Pounds in Six Week Period 3Health News:Weight Watchers Members and Online Subscribers Lose an Estimated 4 Million Pounds in Six Week Period 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: